- Dec 13, 2019
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
NCT03850522: Phase 2: PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma PD-L1 Peptide Vaccination in High Risk...
59
- Dec 7, 2019
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma
NCT03839459: Phase 2: Denosumab for Smoldering Multiple Myeloma Denosumab for Smoldering Multiple Myeloma This study will assess the...
99
- Dec 6, 2019
NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dex NDMM
Dara-KRd NCT04113018: Phase 2: Study of Daratumumab Combined With Carfilzomib, Lenalidomide and Dexamethasone for Newly Diagnosed...
30
- Dec 6, 2019
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dex or Daratumumab, Bortezomib, & Dex in NDMM Myeloma
NCT03942224: Phase 2: Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed...
181
- Dec 5, 2019
NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy
NCT03820817: Phase 1: Rifaximin in Patients With Monoclonal Gammopathy MGUS Rifaximin in Patients With Monoclonal Gammopathy This trial...
214
- Dec 4, 2019
NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Plasmacytoma
LENAZART Study LEN-AZA-RT NCT04174196: Phase 2: A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma...
47